Children with breakthrough varicella infection requiring hospitalization in Turkey (VARICOMP Study 2008-2013)

dc.authorid0000-0003-1802-2518
dc.authorid0000-0002-1347-5019
dc.authorid0000-0002-4015-4210
dc.authorid0000-0003-4088-3103
dc.authorid0000-0003-1307-0246
dc.authorid0000-0002-0339-0134
dc.authorid0000-0003-2187-4121
dc.contributor.authorDinleyici, Ener Cagri
dc.contributor.authorKurugol, Zafer
dc.contributor.authorKara, Ates
dc.contributor.authorTezer, Hasan
dc.contributor.authorTas, Mehmet Ali
dc.contributor.authorGuler, Ekrem
dc.contributor.authorYasa, Olcay
dc.date.accessioned2025-05-10T19:43:51Z
dc.date.issued2015
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstractIntroduction: Varicella in previously immunized individuals, known as breakthrough varicella. While the majority of breakthrough cases are mild, some may be severe, requiring hospitalization in previously healthy children or children with an underlying condition. Methods: This report, as a part of the prospective national pediatric varicella hospitalizations study (including 29 centers, represent 50% of pediatric population) in Turkey, is aimed to evaluate breakthrough varicella infection requiring hospitalization before the routine use of single-dose live varicella vaccine in national program from 2008 to 2013 (<10% of the pediatric age group received a single-dose vaccine). Results: In the time period, 1939 children were hospitalized due to varicella infection in Turkey; 36 children (20 boys, 16 girls, mean age 68.0+37.6 months, all received single dose live varicella vaccine) with breakthrough varicella infection. Breakthrough varicella infection might be severe in previously healthy children (61.1%) and children with immune-compromising conditions (38.9%). The time elapsed between vaccination and hospitalization was approximately 5 years, and neurological complications, mainly encephalitis and meningitis, were the most common reason for hospitalization in previously healthy children. Conclusion: Pediatric breakthrough varicella requiring hospitalization have been seen in Turkey, is mainly observed in previously healthy children at 5 years after a single-dose varicella vaccine. The varicella vaccine has been implemented as part of the National Immunization Program in Turkey in 2013 (a single dose at age 12 months). Further surveillance in the same settings could evaluate the effectiveness of national immunization with single-dose varicella vaccine at 12 months of age and potential need for second dose of vaccine. (C) 2015 Elsevier Ltd. All rights reserved.
dc.identifier.doi10.1016/j.vaccine.2015.06.029
dc.identifier.endpage3987
dc.identifier.issn0264-410X
dc.identifier.issn1873-2518
dc.identifier.issue32
dc.identifier.pmid26133048
dc.identifier.scopus2-s2.0-84937525441
dc.identifier.scopusqualityQ1
dc.identifier.startpage3983
dc.identifier.urihttps://doi.org/10.1016/j.vaccine.2015.06.029
dc.identifier.urihttps://hdl.handle.net/20.500.14730/10755
dc.identifier.volume33
dc.identifier.wosWOS:000358460500031
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier Sci Ltd
dc.relation.ispartofVaccine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250302
dc.subjectVaricella
dc.subjectChickenpox
dc.subjectVaricella vaccine
dc.subjectBreakthrough varicella
dc.titleChildren with breakthrough varicella infection requiring hospitalization in Turkey (VARICOMP Study 2008-2013)
dc.typeArticle

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
10755.pdf
Boyut:
299.84 KB
Biçim:
Adobe Portable Document Format